BRAF and melanoma: The first inhibitor of mutated BRAF (BRAFi), approved by the FDA (2011) and EMA (2012), was vemurafenib (PLX4032), and other drugs targeting BRAF were later approved, like dabrafenib (GSK2118436), with similar results in melanoma patients (Chapman et al., 2011).